A Longitudinal Examination of FDA Warning and Untitled Letters Issued to Pharmaceutical Companies for Violations in Drug Promotion Standards

Yam Limbu, Christopher McKinley, Valerio Temperini

Research output: Contribution to journalArticleResearchpeer-review

Abstract

This study examined over-time differences in the nature and frequency of Food and Drug Administration warning and untitled letters issued to pharmaceutical companies. Across a 12-year time frame, results indicate that frequency of letters and specific violations rose steadily from 2005 to 2010 but have since fallen dramatically. When infractions do occur, they continue to result from the omission or lack of risk information, misleading/false claims, omission of material facts, and labeling issues. In addition, the findings show that violations occur most frequently on brochures, sales aids, corporate websites, and print ads, with the proportion of violations on Internet media rising consistently over-time. Overall, while these findings offer encouragement to those wary of deceptive marketing practices, given the increased proportion of violations within digital marketing platforms coupled with the rare, yet consistent tendency of companies to misrepresent product risk and/or efficacy information, continued focus must be given to consumer education initiatives.

Original languageEnglish
Pages (from-to)3-23
Number of pages21
JournalJournal of Consumer Affairs
Volume53
Issue number1
DOIs
StatePublished - 1 Mar 2019

Fingerprint

pharmaceutical
promotion
drug
examination
marketing
consumer education
sales
website
Internet
lack
time
Violations
Pharmaceuticals
Drugs
Warning
Food and Drug Administration
Proportion

Cite this

@article{6bf9db4ec624450794e9ae406dfcb269,
title = "A Longitudinal Examination of FDA Warning and Untitled Letters Issued to Pharmaceutical Companies for Violations in Drug Promotion Standards",
abstract = "This study examined over-time differences in the nature and frequency of Food and Drug Administration warning and untitled letters issued to pharmaceutical companies. Across a 12-year time frame, results indicate that frequency of letters and specific violations rose steadily from 2005 to 2010 but have since fallen dramatically. When infractions do occur, they continue to result from the omission or lack of risk information, misleading/false claims, omission of material facts, and labeling issues. In addition, the findings show that violations occur most frequently on brochures, sales aids, corporate websites, and print ads, with the proportion of violations on Internet media rising consistently over-time. Overall, while these findings offer encouragement to those wary of deceptive marketing practices, given the increased proportion of violations within digital marketing platforms coupled with the rare, yet consistent tendency of companies to misrepresent product risk and/or efficacy information, continued focus must be given to consumer education initiatives.",
author = "Yam Limbu and Christopher McKinley and Valerio Temperini",
year = "2019",
month = "3",
day = "1",
doi = "10.1111/joca.12189",
language = "English",
volume = "53",
pages = "3--23",
journal = "Journal of Consumer Affairs",
issn = "0022-0078",
publisher = "Wiley-Blackwell",
number = "1",

}

A Longitudinal Examination of FDA Warning and Untitled Letters Issued to Pharmaceutical Companies for Violations in Drug Promotion Standards. / Limbu, Yam; McKinley, Christopher; Temperini, Valerio.

In: Journal of Consumer Affairs, Vol. 53, No. 1, 01.03.2019, p. 3-23.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A Longitudinal Examination of FDA Warning and Untitled Letters Issued to Pharmaceutical Companies for Violations in Drug Promotion Standards

AU - Limbu, Yam

AU - McKinley, Christopher

AU - Temperini, Valerio

PY - 2019/3/1

Y1 - 2019/3/1

N2 - This study examined over-time differences in the nature and frequency of Food and Drug Administration warning and untitled letters issued to pharmaceutical companies. Across a 12-year time frame, results indicate that frequency of letters and specific violations rose steadily from 2005 to 2010 but have since fallen dramatically. When infractions do occur, they continue to result from the omission or lack of risk information, misleading/false claims, omission of material facts, and labeling issues. In addition, the findings show that violations occur most frequently on brochures, sales aids, corporate websites, and print ads, with the proportion of violations on Internet media rising consistently over-time. Overall, while these findings offer encouragement to those wary of deceptive marketing practices, given the increased proportion of violations within digital marketing platforms coupled with the rare, yet consistent tendency of companies to misrepresent product risk and/or efficacy information, continued focus must be given to consumer education initiatives.

AB - This study examined over-time differences in the nature and frequency of Food and Drug Administration warning and untitled letters issued to pharmaceutical companies. Across a 12-year time frame, results indicate that frequency of letters and specific violations rose steadily from 2005 to 2010 but have since fallen dramatically. When infractions do occur, they continue to result from the omission or lack of risk information, misleading/false claims, omission of material facts, and labeling issues. In addition, the findings show that violations occur most frequently on brochures, sales aids, corporate websites, and print ads, with the proportion of violations on Internet media rising consistently over-time. Overall, while these findings offer encouragement to those wary of deceptive marketing practices, given the increased proportion of violations within digital marketing platforms coupled with the rare, yet consistent tendency of companies to misrepresent product risk and/or efficacy information, continued focus must be given to consumer education initiatives.

UR - http://www.scopus.com/inward/record.url?scp=85045218203&partnerID=8YFLogxK

U2 - 10.1111/joca.12189

DO - 10.1111/joca.12189

M3 - Article

VL - 53

SP - 3

EP - 23

JO - Journal of Consumer Affairs

JF - Journal of Consumer Affairs

SN - 0022-0078

IS - 1

ER -